Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

5.795 -0.065 (-1.11%)
Streaming Delayed Price Updated: 12:29 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Analyst Expectations For ATAI Life Sciences's Future
 
Via Benzinga
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 
From atai Life Sciences
Via GlobeNewswire
Why Atai Life Sciences Stock Was So Lively This Week
The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts. 
Via The Motley Fool
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides
As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035. 
Via Benzinga
Alibaba, Lithium Americas And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
 
Via Benzinga
Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews
 
Via Benzinga
Why Atai Life Sciences Stock Crushed It on Tuesday
Investors cheered good news from the lab delivered by the company. 
Via The Motley Fool
Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients
Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026. 
Via Benzinga
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
Via Investor Brand Network
Topics Artificial Intelligence
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA), 
Via Benzinga
Topics Artificial Intelligence
atai Life Sciences Awarded Grant from the National Institutes of Health
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Atai Life Sciences Revenue Jumps 163%
Via The Motley Fool
Topics Intellectual Property
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
 
Via Benzinga
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile. 
Via Benzinga
What's going on in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Higher As US-EU Ink Trade Deal: Tesla, Palantir, UnitedHealth In Focus
U.S. stock futures rose on Monday after ending higher on Friday. Futures of major benchmark indices were higher. 
Via Benzinga
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga
Top movers in Friday's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.